FDA “Critical Path” May Lead To Changes In Dosing, Active-Control Trials
Executive Summary
FDA's "Critical Path" drug development initiative will explore relaxing the agency's interpretation of active-control trials, Office of Medical Policy Director Robert Temple, MD, said
You may also be interested in...
Detour On FDA’s “Critical Path:” Safety Issues Divert Agency’s Attention
FDA has revised its timeline for the "Critical Path" drug development initiative to reflect more pressing matters, including drug safety issues, Acting Deputy Commissioner for Operations Janet Woodcock said
Biomarker Working Group To Explore Development Of Guidance
An FDA working group will be formed by year-end to consider the development of a guidance on biomarkers
FDA Wants To Be “Model” Agency: Preparing For Clinical Trial Simulations
FDA plans to make greater use of mathematical and statistical models to guide drug development and approval decisions, Center for Drug Evaluation & Research Scientific Advisor Donald Stanski said Oct. 5 at a R&D conference sponsored by Phacilitate in Geneva, Switzerland